Image

Florian Preinfalk

Associate

Florian Preinfalk advises national and international companies on all kind of regulatory questions in the Life Sciences sector.
He further advises on Life Sciences regulatory matters in connection with domestic and cross-border M&A transactions related to pharma, medical device or other life sciences businesses.

Expertise

Industries

Experience

Representative matters

  • Organon on comprehensive regulatory questions on medicinal products and medical devices as well as on corresponding distribution channels, import, pharmacovigilance, and advertising. 
  • Carl Zeiss Meditec in connection with a cloud-based digital health platform as well as the implementation of this health platform in an app. 
  • A global pharmaceutical company on issues relating to the regulation of in vitro diagnostics, in particular the placement on the market of Laboratory Developed Tests (LDTs). 
  • Vision Healthcare, a consumer healthcare company headquartered in Belgium with an extensive portfolio of self-care brands and over-the-counter products in several European countries, on the acquisition of 100% of the shares of AixSwiss BV, a leading provider of probiotic dietary supplements. 
  • Enovis Corporation on an investment in the German digital health start-up Orthopy Health GmbH. 
  • Global pharmaceutical companies in patent litigation cases and related pharmaceutical law and regulatory questions. 
  • Kyowa Kirin International (KKI) on its joint venture collaboration with global science-based, privately owned pharmaceutical company Grünenthal for KKI’s established medicines portfolio.

Published Work

  • Zhuleku, Eda, Günther, Stefanie, Preinfalk, Florian, (2023), “Medical Devices: Sources of Regulation (Germany)”, Thomson Reuters Practical Law

Qualifications

Admissions

Rechtsanwalt, Germany, 2022

Academic

Second German Law Degree, Higher Regional Court of Nuremberg, Germany, 2021

First German Law Degree, University of Passau, Germany, 2018

Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.